Document is current
Any future updates will be listed below
-
Authors
Michel, Maurice
Funuyet-Salas, Jesús
Doll, Michelle
Alqahtani, Saleh A.
Armandi, Angelo
Labenz, Christian
Galle, Peter R.
Schattenberg, Jörn M.
-
Funding
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 20 July 2024
Accepted: 3 September 2024
First Online: 17 September 2024
Competing interests
: JMS reports Consultant: Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Genfit, Gilead Sciences, GSK, Heel GmbH, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Julius Clinical, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shinogi, Siemens Healthcare GmbH, Summit Clinical Research. Research Funding: Gilead Sciences, Boehringer Ingelheim, Nordic Bioscience, Siemens Healthcare GmbH. Speaker Honorarium: MedPublico GmbH, Boehringer Ingelheim. The other authors declare that they have no competing interests.
: Informed consent was obtained from all participants involved in the study.
